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TNP-470, an angiogenesis inhibitor, suppresses the progression
of peritoneal fibrosis in mouse experimental model.
Background. In patients on long-term peritoneal dialysis
(PD), angiogenesis and vasculopathy are observed in the peri-
toneum, and the degree of vascularization correlates with the
area of fibrotic tissue, suggesting the involvement of angiogen-
esis in the progression of peritoneal fibrosis. The aim of the
present study was to evaluate the effect of TNP-470, an anti-
angiogenic compound, on the development of peritoneal fibro-
sis induced by chlorhexidine gluconate (CG).
Methods. Peritoneal fibrosis was induced by injection of CG
into peritoneal cavity of Institute for Cancer Research (ICR)
mice. TNP-470 was injected subcutaneously with CG. Mice were
sacrificed, and peritoneal tissues were dissected out at days eight
and 16 after CG and TNP-470 injection. The expression patterns
of CD31 (as a marker of endothelial cells), vascular endothelial
cell growth factor (VEGF), a-smooth muscle actin (as a marker
of myofibroblasts), heat shock protein 47 (HSP47), type III col-
lagen, F4/80 (as a marker of mice macrophages), proliferating
cell nuclear antigen (PCNA), and cyclin-dependent kinase 2
(Cdk2) were examined by immunohistochemistry.
Results. CG-injected mice showed thickening of the subme-
sothelial zone and increased number of vessels, myofibrob-
lasts, and infiltrating macrophages. The expression levels of
VEGF, type III collagen, and HSP47 were increased, and a
large number of PCNA-positive cells and Cdk2-expressing cells
were observed in the thickened submesothelial area. Treatment
with TNP-470 suppressed the submesothelial zone thickening
and reduced collagen III expression as well as angiogenesis.
TNP-470 also decreased the number of VEGF-expressing cells,
myofibroblasts, macrophages, PCNA-positive cells, and Cdk2-
expressing cells.
Conclusion. Our results indicate the involvement of angio-
genesis in the progression of peritoneal fibrosis, and suggest
that TNP-470 may be potentially useful for the prevention of
peritoneal fibrosis through inhibition of angiogenesis and sup-
pression of myofibroblast proliferation.
Key words: TNP-470, angiogenesis, peritoneal fibrosis, dialysis, inflam-
mation, myofibroblasts.
Received for publication October 16, 2003
and in revised form March 23, 2004, and April 22, 2004
Accepted for publication May 12, 2004
C© 2004 by the International Society of Nephrology
Peritoneal dialysis (PD) is a beneficial therapy for end-
stage renal disease (ESRD), but long-term use of PD in-
duces histopathologic changes in the peritoneum, such as
peritoneal fibrosis with increased submesothelial colla-
gen deposition and loss of mesothelial cells [1–5]. Recent
studies also demonstrated increased peritoneal vascular-
ization with vasculopathy in patients on long-term PD
[3, 6–8]. Furthermore, Honda et al [6] reported the de-
velopment of submesothelial fibrosis and indicated that
at that stage, the appearance of vasculopathy correlated
with a reduction in ultrafiltration. Williams et al [5] also
demonstrated that the prevalence of vasculopathy in-
creased with long-term use of PD, and that the number
of blood vessels in the peritoneum correlated with the
amount of fibrous tissue in PD patients on peritoneal fi-
brosis. Other studies showed that the concentration of
vascular endothelial growth factor (VEGF) in the peri-
toneal fluid was up-regulated in PD patients [9, 10]. These
findings suggest that in peritoneum of PD patients, where
the number of blood vessels is increased, angiogenesis is
associated with the pathogenesis of peritoneal fibrosis.
Angiogenesis, or formation of new blood vessels, oc-
curs during the progression of various pathologic con-
ditions, such as solid tumor growth [11, 12], diabetic
retinopathy [13], and chronic inflammation [14, 15]. It
is widely accepted that the inhibition of angiogenesis is
a suitable strategy to prevent the progression of those
diseases. TNP-470, a synthetic analog of fumagillin, a
natural product of Aspergillus fumigatus, is known as a
potent anti-angiogenic compound [16]. The efficacy of
TNP-470 as an angiogenesis inhibitor has been demon-
strated experimentally in the treatment of hemangiomas
[17], corneal neovascularization [18], collagen-induced
arthritis [19, 20], primary tumors, and metastatic dis-
eases [21–24]. While TNP-470 is known to exert its anti-
angiogenic effect through the preferential inhibition of
endothelial cell proliferation [16, 25], it has been recently
demonstrated that this agent also inhibits proliferation
of fibroblasts [16, 26], vascular smooth muscle cells [27],
hepatic stellate cells [28], and mesangial cells [29].
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The present study was designed to determine the effect
of TNP-470 on the progression of peritoneal fibrosis us-
ing an experimental model of peritoneal fibrosis induced
by chlorhexidine gluconate (CG) injection. Although the
mechanism underlying the development of peritoneal fi-
brosis by CG is not clear, previous research showed that
persistent chemical irritation by CG could induce tissue
damage with inflammation subsequently followed by tis-
sue repair with excessive proliferation of fibroblasts [30].
In addition, we demonstrated previously that during pro-
gressing CG-induced peritoneal fibrosis, the number of
blood vessels also increased. In the present study, we
demonstrated that treatment with TNP-470 reduced the
number of blood vessels, VEGF-expressing cells, prolif-
erating cell nuclear antigen (PCNA)-positive endothelial
cells and myofibroblasts, and cyclin-dependent kinase 2
(Cdk2)-expressing cells, and suppressed the progression
of peritoneal thickening and collagen deposition. Our re-
sults indicate that TNP-470 is effective in preventing the
progression of peritoneal fibrosis in our model.
METHODS
Animal models
The experiments described in this study were con-
ducted in female ICR mice (Japan SLC Inc., Shizuoka,
Japan) of 25 ± 3 g body weight. They were housed in
a light- and temperature-controlled room in Biomedi-
cal Research Center, Center for Frontier Life Sciences,
Nagasaki University. They had free access to laboratory
chow and tap water in standard rodent cages. The exper-
imental protocol was inspected by Animal Care and Use
Committee of Nagasaki University School, and approved
by the President of Nagasaki University School. Peri-
toneal fibrosis was induced by intraperitoneal injection of
0.1% chlorhexidine gluconate (CG) in 15% ethanol dis-
solved in saline, as described previously with some modi-
fications [30, 31]. Mice received injections of CG into the
peritoneal cavity at a volume of 10 mL/kg body weight
every other day (CG group). In another group of mice,
TNP-470 (a kind gift from Takeda Chemical Industries,
Osaka, Japan) dissolved in saline containing 1% ethanol
and 5% gum Arabic (016–00025; Wako Pure Chemical
Industries, Osaka, Japan) was injected subcutaneously
twice per week at a concentration of 20 mg/kg with CG
(CG+TNP470 group). Mice of another group were in-
jected 15% ethanol in saline intraperitoneally (control
group). Each group consisted of 10 mice. The effect of
repeated injections of TNP-470 alone and the vehicle
used to dissolve TNP-470 (saline containing 1% ethanol
and 5% gum Arabic) on the progression of peritoneal
fibrosis were examined. The dose and interval for TNP-
470 injections were selected based on pilot studies con-
ducted to determine the effects of different doses on the
thickness of submesothelial area. TNP-470 doses lower
than 10 mg/kg/week did not reduce peritoneal thickness
compared with nontreated CG mice. Consequently, we
selected 20 mg/kg × 2/week for the present study. CG
(0.1%) and TNP-470 were injected under ether anesthe-
sia to ensure the injection of the correct dose at the correct
site, and to avoid induction of pain during intraperitoneal
injection. Mice were sacrificed at days eight or 16 after
the first CG and TNP-470 injection, and peritoneal tissues
were dissected out carefully. To avoid direct damage to
the peritoneum caused by repeated injections, injections
of CG were made at the lower part of the peritoneum,
while the upper portion of the parietal peritoneum was
used for the following examination. Tissues were fixed
with 4% paraformaldehyde immediately after sampling
and embedded in paraffin.
Histologic and immunohistochemical examination
For morphologic examination, 4-lm thick paraffin-
embedded tissues were stained with hematoxylin and
eosin (H&E). The following antibodies were used for
immunohistochemistry: (1) rat antimouse CD31/
PECAM-1 antibody diluted 1/50 (1625–01; Southern
Biotechnology, Birmingham, AL, USA), which was
used as a marker of endothelial cells; (2) horseradish
peroxidase (HRP)–labeled-dextran polymer-conjugated
mouse anti-a-smooth muscle actin (SMA) antibody
(U7033; Dako, Glostrup, Denmark), which was used
as a marker of myofibroblasts; (3) rabbit anti-type III
collagen antibody diluted 1/200 (LB-1393; LSL Co.,
Tokyo, Japan); (4) mouse anti-heat shock protein (HSP)
47 antibody diluted 1/50 (StressGen, Victoria, British
Columbia, Canada), which is a molecular chaperone
necessary for production of collagen; (5) HRP-labeled
dextran polymer-conjugated mouse anti-PCNA antibody
(U7032; Dako) as a marker of proliferating cells; (6)
rabbit anti-VEGF antibody diluted 1/100 (sc-507; Santa
Cruz Biotechnology, Santa Cruz, CA, USA); (7) rat
anti-F4/80 antibody diluted 1/100 (MCA497; Serotec,
Oxford, UK) as a marker of mouse macrophages; and
(8) mouse anti-Cdk2 antibody, a marker of cell cycle
progression, diluted 1/50 (610145; BD Transduction
Laboratories, San Diego, CA, USA).
Indirect immunohistochemical technique was used for
type III collagen, HSP47, F4/80, and Cdk2. Deparaf-
finized tissue sections were incubated for 30 minutes
with a blocking buffer containing 5% normal goat serum,
5% fetal calf serum, 5% bovine serum albumin, and
20% normal swine serum in phosphate-buffered saline
(PBS). The sections were then reacted with the primary
antibody, and diluted in the same blocking buffer. Af-
ter reacting with anti-type III collagen antibody for one
hour at room temperature, sections were reacted with
HRP-conjugated swine antirabbit immunoglobulin anti-
body (P0399; Dako) diluted 1/50 for 30 minutes at room
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temperature, and a complex of rabbit anti-HRP anti-
body and HRP (Z0113; Dako) diluted 1/100 for 30 min-
utes at room temperature. For HSP47 and Cdk2, sections
were reacted with a complex of anti-HSP47 antibody and
HRP-conjugated rabbit antimouse immunoglobulin anti-
body (Z0109; Dako) diluted 1/100, or a complex of anti-
Cdk2 antibody and HRP-conjugated rabbit antimouse
immunoglobulin antibody diluted 1/100 for one hour at
room temperature, and HRP labeled-dextran polymer-
conjugated goat antirabbit immunoglobulin antibody
(K4002; Dako) for 30 minutes at room temperature.
For F4/80, sections were reacted with HRP-conjugated
rabbit antirat immunoglobulin antibody (Z0147; Dako)
and HRP-conjugated swine antirabbit immunoglobu-
lin antibody after reacting with anti-F4/80 antibody for
one hour at room temperature. We used direct immuno-
histochemical technique for a-SMA and PCNA stain-
ing. After deparaffinization, the sections were incubated
for 30 minutes with a blocking buffer similar to that
described above, and then reacted with anti-a-SMA
antibody or anti-PCNA antibody for 1 hour at room tem-
perature. For CD31 and VEGF staining, deparaffinized
tissues were stained with avidin-biotin complex technique
using Vectastain Elite ABC kit (Vector Laboratories,
Burlingame, CA, USA) after reacting with first antibody
for 16 hours at 4◦C. Reaction products were visualized
by treating sections with H2O2 and 3–3 diaminobenzi-
dine tetrahydrochloride. Finally, the sections were coun-
terstained with methyl green and mounted. For all
specimens, negative controls were prepared with irrel-
evant mouse monoclonal antibody, rat monoclonal anti-
body, or the normal rabbit IgG in place of the primary
antibody.
Double staining for CD31 and PCNA was also per-
formed. After the CD31 staining step as described above,
sections were washed in PBS to stop the color reaction,
and incubated with double staining enhancer (50–056;
Zymed Laboratories, Inc., San Francisco, CA, USA).
Thereafter, they were reacted with anti-PCNA antibody
followed by incubation with HRP-conjugated antibodies
as mentioned above. A second chromogen, True blue (71–
00-64; KPL, Gaithersburg, MD, USA) was then applied,
which stained positive cells in blue. The tissue sections
were not counterstained with methyl green because this
counterstaining could interfere with the color from the
chromogen.
Morphometric analysis
To assess the extent of peritoneal thickening, we used
digitized images and image analysis software (Win ROOF
MITANICORP, Chiba, Japan). We measured the thick-
ness of the submesothelial zone above the abdominal
muscle in cross-sections of the abdominal wall. The im-
age was transformed into a matrix of 1280 × 1000 pixels
and viewed at ×100 magnification. We selected a width of
840 lm in the examined field under the microscope and
measured the area of the submesothelial layer within the
selected width of 840 lm. For each sample, eight such
areas were selected and the average area of the subme-
sothelial layer was determined.
In each peritoneal sample, the numbers of CD31-
positive vessels, a-SMA–expressing cells, HSP47-
expressing cells, PCNA-positive cells, VEGF-expressing
cells, F4/80-positive macrophages, and Cdk2-expressing
cells were counted in 10 fields at ×400 magnification.
We also counted the number of cells double-positive
for CD31 and PCNA at 10 fields under ×400 magnifi-
cation in each group, and calculated the percentage of
double-positive cells in CD31-expressing cells.
Statistical analysis
Data are expressed as mean ± SD. Differences among
groups were examined for statistical significance using
repeated measures analysis of variance (ANOVA) (Bon-
ferroni/Dunn test). A P value less than 0.05 denoted the
presence of statistically significant difference.
RESULTS
Morphologic examination
Morphologic changes were assessed by H&E staining.
In the normal mouse, the peritoneal tissue consisted of
peritoneal mesothelial monolayer and exiguity of con-
nective tissues under the mesothelial layer (Fig. 1A).
The peritoneal samples of mice of the CG group showed
marked thickening of the submesothelial compact zone
and the presence of numerous cells. The submesothe-
lial zone showed progressive thickening to day 16 (day
eight; Fig. 1B, day 16; Fig. 1C). At day eight, there were
no appreciable differences in the submesothelial zone
thickness between the CG and CG+TNP-470 groups
(Figs. 1D and 2). At day 16, the thickness of the sub-
mesothelial zone and the number of infiltrating cells in
CG+TNP-470-treated mice were significantly less than
those of CG-treated mice (Figs. 1E and 2). Peritoneal
tissues of control mice were almost normal without any
thickening of the submesothelial zone (Fig. 1F). Re-
peated injections of TNP-470 alone did not affect the
thickening of the peritoneum compared with the control
(Fig. 1G) and the severity of submesothelial area thick-
ening in mice injected with CG and the vehicle used to
dissolve TNP-470 was similar to that in CG injected mice
(Fig. 1H).
Expression of CD31 and VEGF
Recent studies described the presence of increased
number of vessels in thickened peritoneal tissues of peri-
toneal dialysis (PD) patients [5, 8] and animal models
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Fig. 1. Hematoxylin and eosin staining of peritoneal tissues. In normal
mice, note the monolayer of mesothelial cells covered with the surface
of peritoneum (A). Chlorhexidine gluconate (CG) injection induced
significant thickening of the peritoneum at days 8 (B) and 16 (C). Ad-
ministration of TNP-470 in CG-treated mice significantly suppressed
the progression of peritoneal thickening at day 16 (E) but not at day 8
(D). In control mice injected with 15% ethanol/saline, the peritoneum
is only slightly thickened at day 16 (F). Repeated injections of TNP-470
without CG had no effect on peritoneal thickening compared with con-
trol mice (G), and injection of the vehicle used for dissolving TNP-470
with CG did not alter the thickening of peritoneum compared to mice
injected with CG alone (H). Bars, the area of submesothelial compact
zone. Magnification: ×100.
of experimental peritoneal fibrosis [30, 32]. Therefore,
we quantified the number of blood vessels using im-
munohistochemistry for CD31. The number of CD31-
positive vessels was markedly increased in mice of the
CG group (Fig. 3A). TNP-470 administration decreased
the number of CD31-expressing vessels (Fig. 3B). We
also examined VEGF expression in the submesothe-























Fig. 2. The area of submesothelial fibrotic tissue in control group, CG
group, and CG+TNP470-treated group at day 8 (left) and day 16 (right).
Data are mean ± SD. The area of submesothelial fibrotic tissue was
measured with the range of 840 lm. Submesothelial area in CG group
is significantly increased compared with control group at days 8 and 16,
while administration of TNP-470 significantly reduced the progression
of submesothelial thickening in CG+TNP470 group at day 16. ∗P <
0.01 vs. control. ∗∗P < 0.05 vs. control. #P < 0.01 vs. CG-treated mice.
Fig. 3. Immunohistochemistry for CD31 and VEGF at day 16. Note the
presence of numerous vessels positively stained for CD31 (arrowheads)
in CG group (A), while a few vessels are stained for CD31 (arrowheads)
in CG+TNP470 group (B). Magnification: ×300. Note the large number
of VEGF-expressing cells in the CG group (C). VEGF-positive cells
were peritoneal mesothelial cells (E), vascular endothelial cells (F),
and fibroblast-like cells (G). TNP-470 treatment markedly decreased
the number of these cells (D) in the thickened submesothelial zone.
Magnification: (C and D): ×200; (E, F, and G): ×800.
the peritoneal mesothelial monolayer (data not shown).
Treatment with CG markedly increased the number
of VEGF-expressing cells compared with the control,
and the types of cells positive for VEGF were peri-
toneal mesothelial cells (Fig. 3E), vascular endothelial
cells (Fig. 3F), and spindle-shaped fibroblasts (Fig. 3G).
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Table 1. Results of immunohistochemistry for CD31, VEGF,
a-SMA, HSP47, and F4/80
Number of positive cells in the peritoneum
Control group CG group CG+TNP470 group
CD31 0.6 ± 0.6 32.4 ± 7.4a 16.6 ± 6.4b
VEGF 20.6 ± 5.2 205.8 ± 52.4a 82.3 ± 18.9b
a-SMA 6.3 ± 2.7 203.4 ± 69.0a 79.6 ± 38.0b
HSP47 23.7 ± 4.4 207 ± 20.9a 82.8 ± 18.2b
F4/80 0.7 ± 1.0 45.4 ± 9.8a 16.8 ± 6.0b
Data are mean ± SD. The numbers of CD31-positive vessels, VEGF-expressing
cells, a-SMA–expressing cells, HSP47-expressing cells, and F4/80-positive cells
were determined in 10 fields of the submesothelial region selected at random in
each mouse and examined at ×400 magnification.
aP < 0.01 vs. control group.
bP < 0.01 vs. CG group.
Fig. 4. Immunohistochemistry for a-SMA (A and B), HSP47 (C and
D), and type III collagen at day 16 (E and F). In CG group, note the pres-
ence of a large number of a-SMA–positive cells in the submesothelial
zone at day 16 (A). The number of a-SMA is reduced in CG+TNP470
group (B). Note the strong expression of HSP47 in the thickened sub-
mesothelial in CG group (C), while such expression is decreased in
CG+TNP470 group at 16 days (D). In CG group, type III collagen is
strongly expressed in the submesothelial compact zone (E), but it is
clearly decreased in CG+TNP470 group at day 16 (F). Magnification:
×200.
Meanwhile, peritoneal tissues of CG+TNP-470 mice con-
tained fewer VEGF-expressing cells in the submesothe-
lial zone compared with the CG-treated mice (Fig. 3D).
Table 1 summarizes the results of quantitative analysis of
CD31-positive vessels and VEGF-expressing cells in the
submesothelial zone at day 16 for the three groups.
Fig. 5. Immunohistochemistry for F4/80 at day 16. F4/80-expressing
cells are present in thickened peritoneal tissues in CG group (A). Com-
pared with CG group, the number of F4/80-positive cells is reduced in
CG+TNP470 group (B). Magnification: ×200.
Expression of a-SMA, HSP47, and type III collagen
The results of immunohistochemical analyses for a-
SMA, HSP47, and type III collagen at day 16 are shown
in Figure 4 and Table 1. In the control group, the expres-
sion of a-SMA was only observed in vascular smooth
muscle cells (data not shown). In contrast, in mice of
the CG group, a-SMA expression was found in myofi-
broblasts in addition to vascular smooth muscle cells, and
numerous a-SMA–expressing myofibroblasts were iden-
tified in the thickened peritoneal tissues (Fig. 4A). Com-
pared with the CG group, the number of a-SMA–
positive myofibroblasts was markedly reduced in the
CG+TNP-470 group (Fig. 4B). Similarly, HSP47 expres-
sion was limited to mesothelial cells in the control group
(data not shown). In CG group, the number of HSP47-
positive cells was higher, and most of HSP47-positive
cells were mesothelial cells and spindle-shaped fibrob-
lasts in the thickened submesothelial zone, based on mor-
phologic criteria (Fig. 4C). Treatment of mice with CG
and TNP-470 resulted in reduction of HSP47-positive cell
count in the peritoneum, compared with the CG group
(Fig. 4D, Table 1). We also investigated the peritoneal
expression of type III collagen by immunohistochem-
istry. In the CG group, type III collagen was diffusely
expressed in the submesothelial zone (Fig. 4E), while
TNP-470 treatment reduced type III collagen expression
(Fig. 4F).
Expression of F4/80, PCNA, and Cdk2
To identify the type of cells infiltrating the submesothe-
lial zone, we stained sections with anti-F4/80 antibody, a
marker of mouse macrophages. In CG group, a large num-
ber of F4/80-positive macrophages was observed in the
thickened peritoneal tissues compared with the control
(Fig. 5A, Table 1), while TNP-470 treatment markedly
reduced their number (Fig. 5B).
We also examined the antiproliferative effect of TNP-
470 in peritoneal fibrosis by PCNA staining. Treat-
ment with CG resulted in the appearance of numerous
PCNA-positive cells in the thickened submesothelial area
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Fig. 6. Immunohistochemistry for PCNA. In CG group, note the strong expression of PCNA positive cells in the markedly thickened submesothelial
area (A) and among vascular endothelial cells (arrowheads) (C). Cells positive for PCNA were decreased in number in the submesothelial area
in CG+TNP470 group at 16 days (B), especially in vessels (arrowheads) (D). Double staining for CD31 (brown) and PCNA (blue) in the same
section. Note that CD31-positive cells are also positive for PCNA (E). Magnification: (A and B): ×100; (C and D): ×400; (E): ×800. ∗Vessels.
(Fig. 6A), and those cells were peritoneal mesothelial
cells, fibroblast-like spindle-shaped cells, and vascular en-
dothelial cells (Fig. 6C). Compared with CG group, treat-
ment with TNP-470 significantly reduced the number of
PCNA-expressing cells (Fig. 6B), especially vascular en-
dothelial cells (Fig. 6D, Table 2), in peritoneal tissues.
We also examined the antiproliferative effect of TNP-
470 on endothelial cells using double staining for CD31
and PCNA (Fig. 6E). In the CG group, 72.9 ± 6.6% of
CD31-positive cells were stained for PCNA in the subme-
sothelial zone, while only 27.6 ± 7.5% of CD31-positive
cells expressed PCNA in TNP-470 group. With regard to
Cdk2 expression, the number of Cdk2-expressing cells
in the CG group was higher than the control (Fig. 7A).
Cdk2 expression was identified on vascular endothelial
cells, spindle-shaped fibroblasts, and some mesothelial
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Table 2. Results of immunohistochemistry for PCNA, double
staining for PCNA/CD31, and immunohistochemistry for Cdk2
Number of positive cells in the peritoneum
Control group CG group CG+TNP470 group
PCNA 9.3 ± 3.8 244.4 ± 54.6a 71.9 ± 19.5b
PCNA/CD31 NE 177.9 ± 39.8 19.8 ± 5.4b
Cdk2 18.0 ± 5.7 176 ± 40a 73.5 ± 11.7b
Data are mean ± SD. NE; not examined. The numbers of PCNA-positive
cells, PCNA/CD31 double-positive cells, and Cdk2-expressing cells were
determined in 10 fields of the submesothelial region selected at random at ×400
magnification.
aP < 0.01 vs. control group.
bP < 0.01 vs. CG group.
Fig. 7. Immunohistochemistry for Cdk2. Note the large number of
Cdk2-positive cells in the CG group (A), but fewer such cells in
CG+TNP470 group (B). Magnification: ×200.
cells, and expression pattern of Cdk2 was similar to that of
PCNA in CG group. Compared with CG group, TNP-470
treatment reduced the number of Cdk2-expressing cells
in the thickened submesothelial area (Fig. 7B). These data
are summarized in Table 2.
DISCUSSION
In the present study, we demonstrated that administra-
tion of TNP-470 markedly reduced the number of blood
vessels and myofibroblasts in the experimental mouse
model induced by CG for peritoneal fibrosis. Moreover,
treatment with TNP-470 diminished collagen accumula-
tion in the thickened submesothelial area. These findings
indicate that TNP-470 might be useful in preventing the
progression of peritoneal fibrosis, and that angiogenesis
is involved, at least in part, in the development of peri-
toneal fibrosis.
In this study, we demonstrated that administration of
TNP-470 in CG-treated mice reduced the number of
CD31-positive vessels in the thickened submesothelial
area. TNP-470 exerts its antiangiogenic effect through
the inhibition of endothelial cell proliferation and migra-
tion [16, 33, 34]. In fact, immunohistochemical staining
for PCNA revealed that most of the vascular endothelial
cells were proliferating in CG-injected mice, whereas the
number of PCNA-positive vascular endothelial cells in
thickened submesothelial area was comparatively lower
in TNP-470–treated mice, accompanied by reduction of
peritoneal fibrosis. Furthermore, we showed that Cdk-2,
a molecule associated with cell cycle, was also involved in
the inhibitory action of TNP-470 on peritoneal fibrosis.
Increased expression of Cdk2 in the thickened peritoneal
tissue was suppressed by TNP-470. These findings suggest
that the angioinhibitory action of TNP-470 is likely to be
involved in the suppression of peritoneal fibrosis in our
experimental model, although the relationship between
angiogenesis and fibrosis remains an important issue.
In recent studies, accumulating evidences link inflam-
mation to angiogenesis in a variety of chronic inflamma-
tory diseases [14, 15], and the benefits of antiangiogenic
agents have been demonstrated [35]. For instance, in both
adjuvant arthritis and collagen-induced arthritis in rats,
Brahn et al [19, 36] reported that TNP-470 prevented the
development of arthritis and reversed the established dis-
ease. Taxol, which can induce endothelial cell apoptosis,
was also effective in an animal model of arthritis [19, 37].
In chronic inflammation, antiangiogenic therapy results
in anti-inflammatory responses, and its effect is proba-
bly mediated through several mechanisms. Increasing the
vasculature in any tissue expands the route of ingress
for immune cells into inflammatory sites [38]. In addi-
tion, vascular endothelial cells themselves are known to
summon inflammatory cells (monocytes and neutrophils)
through increased expression of adhesion molecules, in-
cluding vascular endothelial cell adhesion molecule-1 [39,
40], intercellular adhesion molecule-1[41], and E- and P-
selectins [42]. Thus, decreasing the vasculature and en-
dothelial cells in vessels may reduce cell infiltration and
delete a potent source of proinflammatory cytokines and
chemokines in inflammatory sites. In the present study,
we demonstrated that treatment with TNP-470 resulted
in a reduction of the number of infiltrating macrophages
concurrent with inhibition of progression of peritoneal
fibrosis, which were induced by CG injection. In CG-
induced peritoneal fibrosis model, it is suggested that an-
giogenesis observed in the thickened submesothelial area
contributes to the progression of peritoneal inflamma-
tion, which leads to peritoneal fibrosis. These results allow
us to speculate that decreased inflammatory responses
were a consequence of the antiangiogenic property of
TNP-470 and may explain the abrogation of qualitative
fibrotic response during the progression of peritoneal
fibrosis.
Our results also showed that TNP-470 treatment re-
duced the number of PCNA-positive nonendothelial
fibroblast-like cells, as well as PCNA-positive endothelial
cells in the thickened submesothelial area. These results
suggest that administration of TNP-470 might have an an-
tiproliferative effect on myofibroblasts in the thickened
peritoneal tissues. In a previous in vivo study, adminis-
tration of TNP-470 in rats with anti-Thy-1.1 antibody-
induced glomerulonephritis resulted in the suppression
of mesangial cell proliferation and extracellular matrix
expansion in glomeruli [29]. In addition, Yan et al [28]
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also documented that treatment with TNP-470 could pre-
vent the progression of hepatic fibrosis by inhibiting the
proliferation of hepatic stellate cells in a rat model of
carbon tetrachloride- and dimethylnitrosamine-induced
hepatic fibrosis. Interestingly, our results also showed a
reduction of collagen accumulation in the submesothelial
area of TNP-470–treated mice. One possible explanation
for the inhibition of collagen accumulation by TNP-470
in our model could be drawn from the negative mito-
genic effects of TNP-470 on myofibroblasts, which are
the major source of collagen production [43, 44]. Our
results showed that the expression of HSP47, a collagen-
specific molecular chaperone [45], was decreased in the
submesothelial area of TNP-470–treated mice. There-
fore, prevention of peritoneal fibrosis in our model by
TNP-470 can be explained by two mechanisms: (1) in-
hibition of angiogenesis; and (2) suppression of myofi-
broblast proliferation in the submesothelial area. In a
previous study, Margetts et al [32] demonstrated a re-
duction of peritoneal-associated vessels by gene transfer
therapy of angiostatin, a potent inhibitor of endothelial
cell proliferation in an experimental model of peritoneal
fibrosis induced by chronic infusion of PD solution. They
also observed a reduction of submesothelial thickening,
although such effect was not statistically significant. We
postulate that the antiangiogenic and antiproliferative ef-
fects of TNP-470 may have a mutually potentiating effect
in suppressing the progression of peritoneal fibrosis in our
model.
In the present study, we induced peritoneal fibrosis by
intraperitoneal injection of CG. CG-induced peritoneal
fibrosis does not mimic peritoneal sclerosis or encapsu-
lating peritoneal sclerosis observed in patients on long-
term PD. The underlying mechanisms of encapsulating
peritoneal sclerosis are not fully understood, making it a
difficult disease to model. In the CG-induced peritoneal
fibrosis model, the number of vessels was increased in
the submesothelial area, together with collagen deposi-
tion and thickening of the peritoneum [30]. In addition,
treatment with antisense oligonucleotide for HSP47 in-
hibited the thickening of submesothelial area, suppressed
collagen deposition, and reduced the number of vessels
in this model [31]. The results of these previous stud-
ies suggest a link between angiogenesis and the devel-
opment of peritoneal fibrosis and collagen accumulation.
Based on these properties, we used this model to investi-
gate the efficacy of TNP-470 on peritoneal fibrosis. While
we do not think that the CG-induced peritoneal fibrosis
equates with human peritoneal fibrosis, our model does
exhibit the key pathologic features of human peritoneal
sclerosis, including increased expression of collagen type
III, HSP47, and a-SMA, macrophage infiltration, and in-
creased expression of VEGF. Thus, the pathologic mecha-
nisms discerned in the mouse are worthy of consideration
in human.
CONCLUSION
We demonstrated that TNP-470 has antiangiogenic and
antiproliferative effects in a mouse model of chemically
induced peritoneal fibrosis. Our results suggest that an-
giogenesis, together with fibroblast proliferation, is an
important process in the pathologic progression of peri-
toneal fibrosis.
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